Isabelle Sinapi

Impact of the tumor immune contexture in microsatellite-stable metastatic colorectal cancer treated with avelumab, cetuximab, and irinotecan

Nicolas D. Huyghe, Elena Benidovskaya, Tariq Masoodi, Isabelle Sinapi et autres

The treatment of patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) remains a significant clinical challenge. Cetuximab, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb), induces immunogenic cell death, potentially synergizing with immune checkpoint inhibitors. The phase 2, proof-of-concept, single-arm AVETUXIRI …

be, qa, us, fr (code pays fourni par la source)

Patient and physician expectations regarding disease and treatment of advanced HCC: The prospective PERCEPTION1 study

Jean‐Charles Nault, Nanthara Sritharan, Gontran Verset, Ivan Borbath et autres

Background We aim to explore patient expectations regarding their treatments and prognosis in comparison to physicians' assessments in patients with advanced hepatocellular carcinoma (HCC) receiving systemic treatments. Methods We prospectively enrolled 205 patients in France and Belgium with BCLC B/C HCC receiving …

fr, be (code pays fourni par la source)

Efficacy and safety of short-course radiotherapy versus total neoadjuvant therapy in older rectal cancer patients: a randomised pragmatic trial (SHAPERS)

Rita Saúde-Conde, Timon Vandamme, Mickaël De Backer, Philippe Martinive et autres

Although total neoadjuvant therapy (TNT) is a new standard of care for locally advanced rectal cancer (LARC), there are no data to confirm the safety and efficacy of this approach in older patients. SHAPERS is a multicentre, open-label, randomised pragmatic trial, aiming …

be, us, fr (code pays fourni par la source)

120P Avelumab (AVE), cetuximab (CET) and irinotecan (IRI) for treatment refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Characterization of the circulating immune response in the AVETUXIRI phase II trial

Elena Benidovskaya, Nicolas D. Huyghe, Javier Carrasco, Astrid De Cuyper et autres

be, fr (code pays fourni par la source)

635P Avelumab (AVE) combined with cetuximab (CET) and irinotecan (IRI) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): The AVETUXIRI phase II study

Marc Van den Eynde, Nicolas D. Huyghe, Isabelle Sinapi, Astrid De Cuyper et autres

be, qa, fr (code pays fourni par la source)

599P R-IMMUNE: A phase Ib/II study to evaluate safety and efficacy of atezolizumab combined with radio-chemotherapy in a preoperative setting for patients with locally advanced rectal cancer (LARC)

Javier Carrasco, G. Beniuga, Anne Jouret‐Mourin, Paméla Baldin et autres

be (code pays fourni par la source)

2237P Avelumab (AVE), cetuximab (CET) and irinotecan (IRI) for treatment refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Translational analyses of the AVETUXIRI phase II trial

Nicolas D. Huyghe, Elena Benidovskaya, Tariq Masoodi, Jaime David Sevilla Carrasco et autres

be, qa, fr (code pays fourni par la source)

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Robin Kate Kelley, Makoto Ueno, Changhoon Yoo, Richard S. Finn et autres

us, jp, kr, cn, hk, nl, be, fr, cl, de, gb (code pays fourni par la source)

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Robin Kate Kelley, Makoto Ueno, Chris Verslype, Diego Kaen et autres

Homogeneity of pathological response (PR) and histopathological growth pattern (HGP) in resected colorectal liver metastases (CRLM) are associated with favorable survival outcome after surgery.

Paméla Baldin, G. Beniuga, Javier Carrasco, Astrid De Cuyper et autres

3596 Background: Surgical resection of CRLM aims to maximize patient survival. However, recurrence rates remain high post-surgery. We previously reported the prognostic relevance of tumor regression grading (TRG) and HGP of resected CRLM. Several studies reported the association of tumoral heterogeneity with …

be, fr (code pays fourni par la source)

Interim analysis of the phase II AVETUXIRI trial: Avelumab combined with cetuximab and irinotecan for treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC).

Nicolas D. Huyghe, Astrid De Cuyper, Isabelle Sinapi, Fazulur Rehaman Vempalli et autres

3595 Background: Immune checkpoint inhibitors demonstrated poor efficacy in MSS mCRC. Cetuximab (anti-EGFR inhibitor) could initiate, independently from RAS mutation, an immunogenic tumor cell death and mediate antitumor immune response. In this trial, we aim to explore the clinical efficacy and safety …

be, fr, us (code pays fourni par la source)

Randomized Phase 2 Study Comparing Pathological Responses of Resected Colorectal Cancer Metastases after Bevacizumab with mFOLFOX6 or FOLFIRI (BEV-ONCO Trial)

Paméla Baldin, Javier Carrasco, Gabriela Beniuga, Anne Jouret‐Mourin et autres

Retrospective studies reported that preoperative oxaliplatin-based chemotherapy increased pathological response (PR) in patients resected for colorectal liver metastases (CRLM). This multicenter prospective randomized (1/1) phase II trial evaluated PR on resected CRLM after preoperative mFOLFOX6 (arm A) or FOLFIRI (arm B) + …

be (code pays fourni par la source)